Long‐term analysis of the benefit of prophylaxis for adult patients with severe or moderate haemophilia A-Reference-Cited by-同舟云学术

Long‐term analysis of the benefit of prophylaxis for adult patients with severe or moderate haemophilia A

Published:2020-04-15 Issue:3 Volume:26 Page:467-477
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Miesbach Wolfgang¹^ORCID,Kittler Sabine²^ORCID,Bauhofer Artur²,Königs Christoph³^ORCID,Becker Thomas²,Nemes László⁴,Staus Alexander²,Schüttrumpf Jörg²

Affiliation:

1. Haemophilia Centre Medical Clinic 2 Institute of Transfusion Medicine University Hospital Frankfurt Frankfurt/Main Germany

2. Biotest AG Dreieich Germany

3. Haemophilia Centre Department of Paediatrics University Hospital Frankfurt Goethe University Frankfurt/Main Germany

4. National Haemophilia Centre and Haemostasis Department Medical Centre Hungarian Defence Forces Budapest Hungary

Funder

Bayer

Biogen

Chugai Pharmaceutical

Novo Nordisk

Pfizer

Roche

Gilead Sciences

Bundesministerium für Bildung und Forschung

Erzincan Üniversitesi

Seventh Framework Programme

Horizon 2020 Framework Programme

Baxalta

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13988

Reference40 articles.

1. Guidelines for the management of hemophilia

2. Definitions in hemophilia: communication from the SSC of the ISTH

3. Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study

4. Prophylaxis in haemophilia should be life‐long;Makris M;Blood Transfus,2012

5. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A descriptive survey of patient experiences and access to specialty medicines with alternative funding programs;2024-06-30

2. Disease Burden, Clinical Outcomes, and Quality of Life in People with Hemophilia A without Inhibitors in Europe: Analyses from CHESS II/CHESS PAEDs;TH Open;2024-04

3. Bleeding pattern and consumption of factor VIII concentrate in adult patients with haemophilia A without inhibitors in the Czech Republic between 2013 and 2021 (Czech National Haemophilia Programme registry data);Annals of Hematology;2023-09-23

4. Gentherapie der Hämophilie;Immunität nach Virusinfektionen;2023-06-22

5. Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature;Haemophilia;2022-10-12